Jefferies Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Jefferies Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,699	Closed	-$174K	–	2704
2018 Q3	$174K	Buy	+11,699	New	+$184K	﹤0.01%	2138

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jefferies Group's CNCE Position: Q4 2018 in Review

Jefferies Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 11,699 shares — an estimated $174K sold.

Jefferies Group first reported a position in CNCE in Q3 2018 and held it in 1 quarter. The position peaked at $174K in Q3 2018. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

Jefferies Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Jefferies Group sold 11,699 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $174K.
Jefferies Group first reported a position in Concert Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
Jefferies Group's Concert Pharmaceuticals, Inc. position peaked at $174K in Q3 2018.
93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Jefferies Group's 13F filing for Q4 2018, filed 14 Feb 2019.